Bill Text: NJ A4094 | 2016-2017 | Regular Session | Introduced
Bill Title: Requires epinephrine auto-injectors to be packaged and sold as single units.
Spectrum: Partisan Bill (Democrat 9-0)
Status: (Engrossed - Dead) 2016-11-03 - Received in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee [A4094 Detail]
Download: New_Jersey-2016-A4094-Introduced.html
Sponsored by:
Assemblyman HERB CONAWAY, JR.
District 7 (Burlington)
SYNOPSIS
Requires epinephrine auto-injectors to be packaged and sold as single units.
CURRENT VERSION OF TEXT
As introduced.
An Act concerning epinephrine auto-injectors and supplementing Title 24 of the Revised Statutes.
Be It Enacted by the Senate and General Assembly of the State of New Jersey:
1. a. A business that is engaged in the manufacture, marketing, or distribution of epinephrine auto-injectors for dispensing to patients in this State shall not market and distribute epinephrine auto-injectors in a fashion that requires a patient to purchase multiple epinephrine auto-injectors in a single transaction.
b. A business that, on the effective date of this act, is authorized by the federal Food and Drug Administration to manufacture, market, or distribute epinephrine auto-injectors in packaging containing more than a single epinephrine auto-injector shall immediately apply for approval to manufacture, market, or distribute epinephrine auto-injectors in packaging containing a single epinephrine auto-injector.
2. This act shall take effect immediately.
STATEMENT
This act would prohibit a business that is engaged in the manufacture or distribution of epinephrine auto-injectors for dispensing to patients in this State from marketing or distributing epinephrine auto-injectors in a fashion that requires a patient to purchase multiple epinephrine auto-injectors in a single transaction. A business that, on the effective date of this act, is authorized by the federal Food and Drug Administration to manufacture or distribute epinephrine auto-injectors in packaging containing more than a single epinephrine auto-injector would be required to immediately apply for approval to manufacture or distribute epinephrine auto-injectors in packaging containing a single epinephrine auto-injector.
Currently, the dominant epinephrine auto-injector product, EpiPen, is sold to consumers only in a package that includes two devices. A single unit package was discontinued in 2011. The bill would require the manufacturer of EpiPen, Mylan, to again make these products available in single unit packages.
